|Specificity:||The antibody MEM-140 reacts with CD25 (Interleukin-2 receptor alpha chain), a 55 kDa type I transmembrane glycoprotein expressed on activated B and T lymphocytes, activated monocytes/macrophages and on CD4+ T lymphocytes (T regulatory cells); it is lost on resting B and T lymphocytes.
HLDA VI; WS Code C C-54
|Immunogen:||PHA-activated peripheral blood leucocytes|
|Preparation:||The purified antibody is conjugated with Biotin-LC-NHS under optimum conditions. The reagent is free of unconjugated biotin.|
|Storage Buffer:||Tris buffered saline (TBS) with 15 mM sodium azide, approx. pH 8.0|
|Storage / Stability:||Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.|
|Usage:||The reagent is designed for Flow Cytometry analysis.
Suggested working dilution is 1:200. Indicated dilution is recommended starting point for use of this product. Working concentrations should be determined by the investigator.
|Expiration:||See vial label|
|Lot Number:||See vial label|
|Background:||CD25 (IL2Ralpha, Tac) is a ligand-binding alpha subunit of interleukin 2 receptor (IL2R). Together with beta and gamma subunit CD25 constitues the high affinity IL2R, whereas CD25 alone serves as the low affinity IL2R. CD25 expression rapidly increases upon T cell activation. The 55 kDa CD25 molecule is enzymatically cleaved and shed from the cell surface as a soluble 45 kDa s-Tac, whose concentration in serum can be used as a marker of T cell activation. Expression of CD25 indicates the neoplastic phenotype of mast cells. Humanized anti CD25 antibodies represent a useful tool to reduce the incidence of allograft rejection as well as the severity of graft versus host reaction, and radioimmunoconjugates of anti-CD25 antibodies can be used against CD25 expressing lymphomas.|
*Lai KN, Leung JC, Lai FM: Soluble interleukin 2 receptor release, interleukin 2 production, and interleukin 2 receptor expression in activated T-lymphocytes in vitro. Pathology. 1991 Jul;23(3):224-8.
*Scheibenbogen C, Keilholz U, Richter M, Andreesen R, Hunstein W: The interleukin-2 receptor in human monocytes and macrophages: regulation of expression and release of the alpha and beta chains (p55 and p75). Res Immunol. 1992 Jan;143(1):33-7.
*Morris JC, Waldmann TA: Advances in interleukin 2 receptor targeted treatment. Ann Rheum Dis. 2000 Nov;59 Suppl 1:i109-14.
*Sotlar K, Horny HP, Simonitsch I, Krokowski M, Aichberger KJ, Mayerhofer M, Printz D, Fritsch G, Valent P: CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol. 2004 Oct;28(10):1319-25.
*Leukocyte Typing VI., Kishimoto T. et al. (Eds.), Garland Publishing Inc. (1997).
For laboratory research only, not for drug, diagnostic or other use.
EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic